Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR183 | P32249 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL56987 | 0.89 | KMT2A (0.51) | GPR183LMNAMEN1POLBKMT2A | |
| SCHEMBL8236980 | 0.87 | ALDH1A1 (0.51) | GPR183MEN1POLBKMT2ASMN1; SMN2 | |
| SCHEMBL57050 | 0.84 | KMT2A (0.47) | GPR183LMNAMEN1POLBKMT2A | |
| SCHEMBL66545 | 0.76 | ALDH1A1 (0.48) | GPR183LMNAMEN1POLBKMT2A | |
| SCHEMBL56480 | 0.75 | SMN1; SMN2 (0.53) | LMNAPOLBSMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL20989309 | 0.74 | GPR183 (0.65) | GPR183POLBSMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL57774 | 0.71 | USP2 (0.44) | LMNAMEN1POLBKMT2ASMN1; SMN2 | |
| SCHEMBL55795 | 0.71 | STS (0.61) | LMNAMEN1KMT2ASMN1; SMN2GAA | |
| SCHEMBL65663 | 0.70 | ALDH1A1 (0.46) | MEN1POLBKMT2ASMN1; SMN2GAA | |
| SCHEMBL11953320 | 0.70 | SMN1; SMN2 (0.61) | MEN1KMT2ASMN1; SMN2RAB9AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129546-B2 | Derivatives for modulation of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-06 | — | — | US | disclosed |
| US-20110077269-A1 | DERIVATIVES FOR MODULATION OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077269-A1 | DERIVATIVES FOR MODULATION OF ION CHANNELS | TRPV1, TRPA1, TRPV2 | GPR183 926/4885LMNA 3617/4885MEN1 4785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.